Efflux Pumps Contribute to Intrinsic Clarithromycin Resistance in Clinical, *Mycobacterium abscessus* Isolates

Qi Guo1,2
Jianhui Chen1,2
Shaoyan Zhang1
Yuzhen Zou1,2
Yongjie Zhang1,2
Dongdong Huang1
Zhemin Zhang1
Bing Li1
Haiqing Chu1,3

1Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, People’s Republic of China; 2Tongji University School of Medicine, Shanghai 200092, People’s Republic of China; 3Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, People’s Republic of China

**Purpose:** The emergence of clarithromycin resistance is a challenge in treating *Mycobacterium abscessus* infections. Known mechanisms that contribute to intrinsic clarithromycin resistance focus on *rrl* gene-related mutations, but resistant clinical isolates often exhibit an inconsistent *rrl* genotype.

**Patients and Methods:** In this study, 194 clinical *Mycobacterium abscessus* isolates were collected from patients with lung infections and the whole genome of each isolate was sequenced. A comprehensive examination of the molecular mechanisms underlying intrinsic clarithromycin resistance was performed, combining MIC determination, comparative genome sequence analysis and qRT-PCR.

**Results:** Of the 194 isolates, 13 (6.7%) were clarithromycin resistant; only seven of these harbored a *rrl* 2270/2271 mutation. The remaining six resistant isolates did not exhibit a specific resistance-associated mutation in the clarithromycin target-site genes, *rrl*, *rrIC*, *rrlD* and *rrlV*, or in the *rrl* modification gene *erm*(41). qRT-PCR analysis showed that the increased expression of the efflux pump genes, MAB_2355c, MAB_1409c and MAB_1846, as well as their positive regulatory gene *whiB7*, consistently correlated with increased clarithromycin resistance. The presence of efflux pump inhibitors significantly decreased the MIC of clarithromycin for nonsusceptible isolates, especially the intrinsic resistant isolates that exhibited no *rrl* 2270/2271 mutation.

**Conclusion:** These findings indicate that efflux pumps play a prominent role in the intrinsic resistance of *M. abscessus* to clarithromycin, complementing other known resistance mechanisms.

**Keywords:** *Mycobacterium abscessus*, clarithromycin resistance, efflux pumps

---

**Introduction**

Infections caused by nontuberculous mycobacteria (NTM) have increased dramatically worldwide in recent years.1–4 *Mycobacterium abscessus* is one of the most common NTM detected. *M. abscessus* infections are difficult to manage because *M. abscessus* is intrinsically resistant to a variety of antimicrobials currently available in clinical practice; infections that are refractory to antibiotic therapy frequently result in morbidity and mortality.5–7 Recently, human-to-human *M. abscessus* transmission was reported, making the problem even more disconcerting.8

Clarithromycin (CLA), which is effective in treating *M. abscessus* lung disease, is recommended as the core agent for treatment of infections although effective therapeutic options are evolving.9,10 The emergence of CLA resistance, however, is
challenging. Currently, a 2270/2271 point mutation (Escherichia coli 2058/2059) in the 23S rRNA (rrl) gene and a full-length erm(41) gene with thymine located at position 28 [erm(41)full-T28 sequevar] are the best described mechanisms conferring CLA resistance. The erm(41)full-T28 sequevar confers induced CLA resistance and a rrl 2270/2271 point mutation confers intrinsic CLA resistance in the M. abscessus isolates assessed. The rrl mutation, however, fails to account fully for the intrinsic resistance to CLA exhibited by M. abscessus. In addition to a rrl 2270/2271 mutation, the expression of a variety of efflux pump genes correlates with CLA resistance in mycobacterium. Almost all the homologous, efflux pump genes are found in M. abscessus; whether these efflux pump genes are involved in the resistance of clinical M. abscessus isolates to CLA remains to be determined.

In this study, the MIC of CLA was determined for 194 clinical M. abscessus isolates collected from patients with lung diseases. A comprehensive exploration of the molecular mechanisms of CLA resistance was performed by combining comparative genome sequence analysis and qRT-PCR; the efflux pump genes were a specific focus. In addition to mutations in the CLA target-site genes, efflux pump genes MAB_2355c, MAB_1409c and MAB_1846 were found to play an important role in CLA resistance. To our knowledge, this is the first comprehensive mechanistic investigation of intrinsic CLA resistance in a large number of clinical, M. abscessus isolates. This work extends our understanding of the factors that affect the resistance of M. abscessus to CLA and suggests novel approaches to treating CLA-resistant infections.

Materials and Methods

Bacterial Isolation and Identification

Between January 2014 and December 2017, 194 M. abscessus isolates were collected at Shanghai Pulmonary Hospital from sputum and bronchoalveolar lavage fluid samples of patients with M. abscessus lung infections. All isolates were preserved in the Clinical Microbiology Laboratory. Species were preliminarily screened for NTM by MGIT960 medium culture and the p-nitrobenzoic acid test, followed by molecular identification of M. abscessus by sequencing the rpoB and erm(41) genes. Each isolate was then stored at –80°C until use.

Clarithromycin Susceptibility Test

CLA susceptibility was determined by the broth microdilution method according to Clinical and Laboratory Standards Institute (CLSI) guidelines; the breakpoints were interpreted according to (CLSI)-M24-A2, as follows: susceptible, MIC ≤ 2 mg/L; intermediate, MIC = 4 mg/L; and resistant, MIC ≥ 8 mg/L. The intrinsic resistance of M. abscessus to CLA was assessed after 3 days exposure. Mycobacterium peregrinum (ATCC 700686; American Type Culture Collection, Manassas, VA, USA) and Staphylococcus aureus (ATCC 29213; American Type Culture Collection, Manassas, VA, USA) served as control reference strains.

Whole-Genome Sequencing and Comparison of Resistance Genes

One hundred ninety-four isolates were sequenced. DNA extraction, library construction and sequencing were conducted by methods previously reported by us. The full genome sequence of each isolate has been published and is available at DDBJ/ENA/GenBank (96 sequences found under bioproject PRJNA488058, 35 under bioproject PRJNA48987 and 63 under bioproject PRJNA398137). Sequence homologs were identified by BLAST and aligned with the homologous sequences of the M. abscessus reference strain ATCC19977 (NC_010397.1). Ribosomal structural genes, rrl, rplC, rplD and rplV, and rrl modification gene erm(41) were also included in this analysis.

RNA Extraction and Quantitative Reverse Transcription PCR (qRT-PCR)

Seven homolog efflux pump genes and the regulatory gene whiB7 (MAB_3508c) correlate with macrolides resistance in mycobacteria, were selected and analyzed. Relative expression of the genes was assessed by comparing the quantity of mRNA expressed by the organism cultured in the presence and absence of CLA using the same technical approach reported previously. A culture incubated in the presence of half its MIC of CLA was shaken at 37°C for 3 h; the RNA was then extracted according to the protocols described by Medjahed et al. cDNA was synthesized using the HiScript III RT SuperMix with gDNA wiper (Vazyme Biotech Co., Ltd). qRT-PCR was performed using ChamQ Universal SYBR Master Mix (Vazyme Biotech Co., Ltd) on a QS6 Real-Time PCR System (Applied Biosystems, Carlsbad, CA). SigA was chosen as the endogenous reference gene. All PCR primer pairs used for amplification are shown in
**Supplementary Table 1.** Calculation of fold change was described previously in detail.\(^a\) Reactions were repeated in triplicate; genes with expression levels ≥4 were considered overexpressed.

**Efflux Pump Inhibition Assay**

The MIC of CLA used in combination with efflux pump inhibitors, phenylalanine-arginine β-naphthylamide (PaβN), carbonyl cyanide 3-chlorophenylhydrazone (CCCP) or verapamil (VP), was determined as previously described.\(^b\)\(^c\)

A 2-fold decrease in MIC in the presence of an inhibitor was considered significant. The efflux pump inhibition test was performed in triplicate.

**Results**

**Clarithromycin Susceptibility and Resistance Profiles**

One hundred ninety-four clinical, *M. abscessus* isolates were collected; 148 isolates belonged to subsp. *abscessus* and 46 isolates belonged to subsp. *massiliense*. The MICs of CLA ranged from 0.06 to 256 mg/L for these isolates; MIC\(_{50}\) and MIC\(_{90}\) at 3 days were 0.5 and 2 mg/L, respectively.

A *rrl* 2270/2271 mutation confers intrinsic resistance to CLA (MIC ≥8 mg/L accessed after 3 days). Accordingly, a comprehensive analysis of the distribution of this resistant genotype and resistance profile among the 194 isolates was performed. A total of 13 (6.7%, 8 subsp. *abscessus* and 5 subsp. *massiliense*) resistant isolates were found. Among these, only 7 (53.8%) of the isolates harbored a *rrl* 2270/2271 mutation while 6 isolates with no *rrl* 2270/2271 mutation also exhibited intrinsic resistance.

**Gene Comparison of *M. abscessus* Isolates**

CLA target-site genes *rrl*, *rplC*, *rplD* and *rplV*, encoding the ribosome structure, were further analyzed among all 194 isolates. Besides the 2270/2271 mutation, 23 additional mutations were observed in *rrl* although none specifically presented in CLA-susceptible or -nonsusceptible isolates (**Supplementary Table 2**). Moreover, no meaningful mutation in ribosome protein genes *rplC*, *rplD* and *rplV* was found in the resistant isolates. The *rrl* modification gene *erm(41)* was also analyzed; no specific sequence changes related to CLA resistance were found.

**Transcriptional Analysis of Efflux Pumps**

The putative efflux pump genes in *M. abscessus* were identified by literature review and analysis of homology to genes found in other *Mycobacterium* strains (**Table 2**). Six CLA-resistant isolates (MIC ≥8 mg/L) harboring a *rrl* mutation and 6 resistant isolates with no *rrl* mutation, along with 6 CLA sensitive (MIC ≤2 mg/L) and 6 CLA intermediate (MIC ≤4 mg/L) isolates were selected at random. The expression of efflux pump genes was quantified by qRT-PCR. Among the 7 putative efflux pump genes analyzed, the transcriptional levels of MAB_2355c (**Figure 1A**), MAB_1409c (**Figure 1B**) and MAB_1846 (**Figure 1C**), as well as their positive regulatory gene *whiB7* (**Figure 1D**), showed consistent increases that correlated inversely with decreases in clarithromycin susceptibility (**Figure 1**). No significant changes in expression of the four remaining putative efflux pump genes were observed after CLA exposure (data not shown). The efflux pump genes in the unexplained (*rrl* mutation-negative) intrinsic resistant isolates showed the highest level of expression. Among the efflux pump genes, for example, MAB_2355c exhibited >40-fold and >20-fold increases in transcription in the *rrl* mutation-negative and *rrl* mutation-positive isolates, respectively.

**Efflux Pump Inhibition Assay**

Previously, three highly expressed genes (MAB_2355c, MAB_1409c and MAB_1846) were found to encode efflux pumps capable of extruding CLA in mycobacteria (15–19). An efflux pump inhibition test was conducted to evaluate the role of these efflux pumps in intrinsic CLA

**Table 1** MIC of Clarithromycin for 194 Clinical *M. abscessus* Isolates

<table>
<thead>
<tr>
<th><em>M. abscessus</em></th>
<th>No. of Isolates</th>
<th>Number of Isolates Exhibiting the MIC (mg/L) of CLA Indicated</th>
<th>No. of Resistant Isolates (%)</th>
<th>Resistant Isolates Harboring a <em>rrl</em> 2270/2271 Mutation*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256</td>
<td>2270/2271 Mutation*</td>
<td></td>
</tr>
<tr>
<td>subsp. <em>abscessus</em></td>
<td>148</td>
<td>16 17 10 30 34 27 6 2 1 0 0 0 0</td>
<td>8 (5.4)</td>
<td>4</td>
</tr>
<tr>
<td>subsp. <em>massiliense</em></td>
<td>46</td>
<td>23 10 3 2 2 1 0 0 0 0 2 1 2</td>
<td>5 (10.9)</td>
<td>3</td>
</tr>
</tbody>
</table>

**Note:** *E. coli numbering 2058 and 2059.
resistance exhibited by M. abscessus. The addition of efflux pump inhibitors PAβN, CCCP and VP significantly decreased the MIC of CLA 47.4%, 52.6% and 63.2%, respectively, for the nonsusceptible isolates while there was no significant effect on the CLA sensitive isolates (Table 3). This decrease was more pronounced in resistant isolates that did not harbor a rrl2270/2271 mutation.

Although the level of efflux pump gene expression was significantly elevated, the inhibitory effect of efflux pump inhibitors was nearly absent in resistant isolates characterized by a rrl2270/2271 mutation.

Discussion
CLA remains the core antibiotic used to treat M. abscessus infections. Treatment options and outcomes differ significantly among patients infected with CLA-resistant versus -sensitive M. abscessus genotypes. In a certain proportion of clinical M. abscessus isolates, resistance cannot be explained by the genotype, alternate mechanisms exist. In this study, 194 isolates were obtained from M. abscessus lung infection cases in mainland China. In addition to CLA-target site mutations, efflux pumps played an important role in the intrinsic resistance of M. abscessus to CLA.

Almost all known mechanisms of intrinsic resistance to CLA involve changes in the CLA binding site due to mutations in rrl (i.e., 2270/2271) or adjacent sites. The results reported provide additional support to indicate that the rrl genotype correctly predicts the CLA-resistant phenotype of most (181/194, 96.9%) clinical isolates. However, 6 (3.1%) intrinsic resistant isolates in this study exhibited an inconsistent, rrl mutation-negative, genotype. Recently, Lipworth and colleagues identified eight potential new resistance-conferring single nucleotide polymorphisms (SNPs) present only in the rrl and erm(41) genes of antibiotic-resistant, but not sensitive, isolates. None of the predicted SNPs or other resistance-conferring SNPs were found in rrl in the current study. Reportedly, mutations in ribosomal protein genes rplC, rplD and rplV are also associated with structural resistance to macrolides. Mutations in these genes, however, were absent among all the CLA-resistant isolates collected in this study.

Efflux was an anticipated factor in the drug resistance exhibited by clinical M. abscessus isolates collected here. Multi-drug efflux pumps directly mediate the resistance of a number of mycobacteria species to CLA. Reportedly, efflux inhibitors reduce the MIC of CLA for M. abscessus. However, CLA-related efflux pumps have not been systematically demonstrated and validated in clinical, M. abscessus isolates specifically. In the present study, three putative efflux pumps (an ATP binding

<table>
<thead>
<tr>
<th>Targeted Gene</th>
<th>Sequence in Reference Strain (NC_010397.1)*</th>
<th>Gene Description</th>
<th>Reference Gene</th>
<th>Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MAB_2355c</td>
<td>2410335-1993</td>
<td>Putative ABC transporter ATP-binding protein</td>
<td>Rv1473</td>
<td>M. tuberculosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>MSMEG_3140</td>
<td>M. smegmatis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>MAV_3306</td>
<td>M. avium</td>
</tr>
<tr>
<td>MAB_1409c</td>
<td>1412431-3702</td>
<td>Putative drug antiporter protein precursor</td>
<td>Rv1258c (top)</td>
<td>M. tuberculosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>MAV_1406</td>
<td>M. avium</td>
</tr>
<tr>
<td>MAB_1846</td>
<td>1844817-6403</td>
<td>Putative ABC transporter ATP-binding protein</td>
<td>Rv2477c</td>
<td>M. tuberculosis</td>
</tr>
<tr>
<td>MAB_3142c</td>
<td>3180588-2105</td>
<td>Putative transmembrane efflux protein</td>
<td>Rv2846c (efpA)</td>
<td>M. tuberculosis</td>
</tr>
<tr>
<td>MAB_2807</td>
<td>2854903-6447</td>
<td>Major facilitator superfamily MFS_1</td>
<td>Rv1410c (p55)</td>
<td>M. tuberculosis</td>
</tr>
<tr>
<td>MAB_0970c</td>
<td>976402-8414</td>
<td>Probable drug resistance transporter</td>
<td>Rv1877</td>
<td>M. tuberculosis</td>
</tr>
<tr>
<td>MAB_1560</td>
<td>1587054-8727</td>
<td>Probable ABC transporter (macrolide-transport) ATP-binding protein</td>
<td>MAV_1695</td>
<td>M. avium</td>
</tr>
</tbody>
</table>

Note: *Complete nucleotide sequence in the M. abscessus genome NCBI database.
cassette efflux pump encoded by MAB_2355c, a tap like efflux pump encoded by MAB_1409c, and an ATP binding cassette efflux pump encoded by MAB_1846) contributed to CLA resistance exhibited by *M. abscessus*. The ATP binding cassette efflux pump encoded by MAB_2355c was the most notable. MAB_2355c is a homolog of genes

Table 3 Efflux Pump Inhibition Decreases the MIC of Clarithromycin for Non-Susceptible Isolates

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Intermediate (n = 6)</th>
<th>Resistant with rrl Mutation (n = 7)</th>
<th>Resistant Without rrl Mutation (n = 6)</th>
<th>Total (n=19)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLA + PaβN</td>
<td>4 (66.7)</td>
<td>0 (0)</td>
<td>5 (83.3)</td>
<td>9 (47.4)</td>
</tr>
<tr>
<td>CLA + CCCP</td>
<td>5 (83.3)</td>
<td>0 (0)</td>
<td>5 (83.3)</td>
<td>10 (52.6)</td>
</tr>
<tr>
<td>CLA + VP</td>
<td>5 (83.3)</td>
<td>1 (14.2)</td>
<td>6 (100)</td>
<td>12 (63.2)</td>
</tr>
</tbody>
</table>

Notes: *Isolates exhibiting MIC ≥4 mg/L after 3 days incubation were considered non-susceptible. After the addition of the inhibitor, a decrease in MIC of ≥2-fold was considered significant.

Abbreviations: PaβN, phenylalanine-arginine β-naphthylamide; CCCP, Carbonyl cyanide 3-chlorophenylhydrazone; VP, verapamil.
Taken together, these findings are consistent with the results reported herein. Additionally, it is generally believed that the induction of efflux pumps is the first event leading to increased antibiotic resistance expressed by Mycobacterium, which usually exhibits low or moderate resistance prior to drug exposure. Similarly, most resistant isolates that lacked the rrrl 2270/2271 mutation exhibited low or moderate resistance in the study reported here (ie, MIC ≤16mg/L, Supplementary Table 3), but exhibit relative higher expression of efflux pumps than do resistant isolates with rrrl 2270/2271 mutation. Moreover, efflux pump inhibitors exerted a greater effect on resistant isolates that lack a rrrl 2270/2271 mutation. As such, we speculate that a change in the target-site (e.g., a rrrl 2270/2271 mutation) is the ultimate event that culminates in a high level of CLA resistance. Efflux pump overexpression, on the other hand, is a reversible, compensatory drug resistance mechanism making efflux pumps a potentially better target for clinical intervention. Whether efflux pump expression affects macrolide resistance induced by functioning erm (41) is currently unknown. Inasmuch as increases in both erm(41) and efflux pump expression reduce CLA sensitivity; however, we speculate that efflux pump expression can further enhance macrolide resistance dependent upon the degree of resistance induced by functional erm(41).

Conclusion
The present study identified three efflux pumps associated with the intrinsic resistance of M. abscessus to clarithromycin. Identification of these pumps adds to our current understanding of the factors that affect drug resistance, and suggests novel approaches to treating CLA-resistant M. abscessus infections.

Ethics Approval and Informed Consent
Ethical approval was not required because the isolates were collected for routine diagnostic testing.

Data Sharing Statement
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Acknowledgments
We sincerely thank Dr. Stephen H. Gregory (Providence, Rhode Island, USA) who helped write and edit this manuscript.

Author Contributions
All authors contributed to data analysis, drafting and revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Funding
This work was funded by grants provided by the: National Natural Science Foundation of China (Nos. 81672063, 81971973 and 81800003), National Science Foundation of Shanghai Municipal Science and Technology Commission (Nos. 18ZR1431600 and 19ZR1442800), Medical Guide Program of Shanghai Science and Technology Committee.
(Nos.18411970600 and 19411969600), New Frontier Technology Joint Project of Municipal Hospital, Shanghai Shenkang Hospital Development Center (No. SHDC12017113), Shanghai Health and Family Planning Commission Excellent Talents Training Program (No. 2018YQ55), General Project of Shanghai Health and Family Planning Commission (201940229), and Project of Top Clinical Medicine Centers and Key Disciplines Construction in Shanghai (No. 2017ZZ0212).

Disclosure
The authors report no conflicts of interest in this work.

References

5. Griffith DE. Mycobacterium abscessus and antibiotic resistance: same as it ever was. Clinical Infectious Diseases. 2019;69(10):1687–1689. doi:10.1093/cid/ciz071


